Gates Foundation Strategic Investment Fund Logo
Share this page:

Press Release: Novel Probiotic Strain Dramatically Reduces Antibiotic Resistance In Infants

Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Global Health Epidemic

DAVIS, Calif., Aug. 14, 2019 /PRNewswire/ — Evolve BioSystems, Inc. today announced findings from a new study that identified healthy, breastfed U.S. infants have alarmingly high levels of antibiotic resistance genes early in life — and how feeding babies a specific strain of Bifidobacterium B. infantis EVC001 — along with breast milk, lowered the total levels of antibiotic resistance genes in the infant gut microbiome by 90 percent, including a near elimination of bacteria such as Escherichia, Clostridium and Staphylococcus. The paper, published in Antimicrobial Resistance and Infection Control, demonstrates that B. infantis EVC001 (commercially known as Evivo® baby probiotic) works uniquely with breast milk to suppress the growth of potentially pathogenic bacteria that harbor the genes responsible for antibiotic resistance. No other probiotic has demonstrated this benefit.

Read the full article here.